Back to Awarded Treatment Trials
Awarded Trial: 01T-106
Grant ID
01T-106
Illness
Schizophrenia
Primary Drug/Intervention
Ethyl Eicosapentanoic Acid
Primary Dosage
0.5 g
Secondary Drug Intervention
Vitamins E and C
Secondary Dosage
364 mg/1000 mg
Other Drug/Intervention
N/A
Other Dosage
N/A
Status
Completed
Investigator
Bentsen
Sample Size
200
Duration of Study Period for Each Subject
16 weeks
Outcome Measurements
PANSS, Global Assessment of Functioning, Quality of Life, UKU Side Effects Rating Scale with four treatment areas: adjunctive EPA or placebo; adjunctive Vitamins E and C or placebo
Results
In a preliminary analysis neither treatment was effective in reducing symptoms. In fact, patients receiving active EPA or Vitamins E and C appeared to worsen relative to placebo.
Publication
Bentsen H, Osnes K2, Refsum H3, Solberg DK3, Bøhmer T. A randomized placebo-controlled trial of an omega-3 fatty acid and vitamins E+C in schizophrenia. Transl Psychiatry. 2013 Dec 17;3:e335.
Link
http://www.ncbi.nlm.nih.gov/pubmed/24346133
PI Name
Håvard Bentsen
Degree
MD
Center
Department of Psychiatry
Institution
Aker University Hospital
Address
Sognsvannsv. 21
City or Town
Oslo
State or Province
N/A
Zip or Postal Code
320
Country
Norway
Email Address
havard.bentsen@medisin.uio.no